Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study

被引：36
作者：
Flannery, Kyle [1 ]
Boyd, Marley [2 ]
Black-Shinn, Jenny [2 ]
Robert, Nicholas [2 ]
Kamat, Ashish M. [3 ]
机构：
[1] Merck & Co Inc, Kenilworth, NJ 07033 USA
[2] US Oncol Network McKesson Specialty Hlth, The Woodlands, TX 77380 USA
[3] Univ Texas MD Anderson Canc Ctr, Div Surg, Dept Urol, Houston, TX 77030 USA
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 12期
关键词：
bladder cancer; cisplatin eligible; patient outcomes; real-world utilization; treatment patterns; PHASE-II TRIAL; TRANSITIONAL-CELL CARCINOMA; UROTHELIAL CARCINOMA; PACLITAXEL; CISPLATIN; CARBOPLATIN; CHEMOTHERAPY; METHOTREXATE; VINBLASTINE; MULTICENTER;
D O I：
10.2217/fon-2018-0654
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: Investigate the effectiveness of chemotherapy for first-line (1L) treatment of metastatic bladder cancer (mBC). Methods: Retrospective cohort study evaluating treatment patterns/outcomes in 1155 mBC patients receiving initial treatment in the community practice setting from January 2010 to June 2014, and followed through July 2016. Results: The most commonly utilized 1L and second-line (2L) regimens were platinum-based and taxane-based, respectively. Median (95% CI) OS for all patients from 1L initiation was 12.8 months (11.7-14.6), and median OS for all 2L regimens was 9.4 months (8.2-11.1). Conclusion: mBC patients eligible for and who received cis-based regimens experienced better OS results. Poor renal function was a key driver of cis-ineligibility. The various monotherapy and combination chemotherapy regimens in 2L produced relatively short OS outcomes.
引用
收藏
页码：1323 / 1334
页数：12
相关论文
共 50 条
  • [41] The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer
    Soria, Francesco
    Moschini, Marco
    Haitel, Andrea
    Wirth, Gregory J.
    Gust, Kilian M.
    Briganti, Alberto
    Roupret, Morgan
    Klatte, Tobias
    Hassler, Melanie R.
    Karakiewicz, Pierre I.
    Shariat, Shahrokh F.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (12) : 533.e1 - 533.e10
  • [42] Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
    Fujii, Hironori
    Matsuhashi, Nobuhisa
    Kitahora, Mika
    Takahashi, Takao
    Hirose, Chiemi
    Iihara, Hirotoshi
    Yamada, Yunami
    Watanabe, Daichi
    Ishihara, Takuma
    Suzuki, Akio
    Yoshida, Kazuhiro
    ONCOLOGIST, 2020, 25 (03) : E469 - E476
  • [43] Effect of neoadjuvant chemotherapy in patients undergoing radical cystectomy for muscle-invasive bladder cancer: a retrospective, multi-institutional study
    Nitta, Masahiro
    Kuroda, Satoshi
    Nagao, Kentaro
    Higure, Taro
    Zakoji, Hidenori
    Miyakita, Hideshi
    Usui, Yukio
    Hasegawa, Masanori
    Kawamura, Yoshiaki
    Shoji, Sunao
    Miyajima, Akira
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (01) : 73 - 79
  • [44] A cost-utility analysis of atezolizumab in the second-line treatment of patients with metastatic bladder cancer
    Parmar, A.
    Richardson, M.
    Coyte, P. C.
    Cheng, S.
    Sander, B.
    Chan, K. K. W.
    CURRENT ONCOLOGY, 2020, 27 (04) : E386 - E394
  • [45] Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study
    Okabe, Ko
    Shindo, Tetsuya
    Maehana, Takeshi
    Nishiyama, Naotaka
    Hashimoto, Kohei
    Itoh, Naoki
    Takahashi, Atsushi
    Taguchi, Keisuke
    Tachiki, Hitoshi
    Tanaka, Toshiaki
    Masumori, Naoya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (10) : 934 - 941
  • [46] First-Line Treatment and Prognostic Factors of Metastatic Bladder Cancer for Platinum-Eligible Patients
    Abida, Wassim
    Bajorin, Dean F.
    Rosenberg, Jonathan E.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2015, 29 (02) : 319 - +
  • [47] Contemporary radical cystectomy outcomes in patients with invasive bladder cancer: a population-based study
    Patel, Manish I.
    Bang, Albert
    Gillatt, David
    Smith, David P.
    BJU INTERNATIONAL, 2015, 116 : 18 - 25
  • [48] Clinical features and management experience in patients with metastatic spinal bladder cancer: a single-institution 10-year retrospective study
    Zhou, Xi
    Liu, Shuzhong
    Yao, Siyuan
    Huo, Zhen
    Wang, Yipeng
    Liu, Yong
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (04) : 3817 - 3825
  • [49] Quality of life in bladder cancer patients receiving medical oncological treatment; a systematic review of the literature
    Taarnhoj, G. A.
    Johansen, C.
    Pappot, H.
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2019, 17 (1)
  • [50] Treatment Patterns and Outcomes by Age in Metastatic Urinary Tract Cancer: A Retrospective Tertiary Cancer Center Analysis
    Tripathi, Nishita
    Gebrael, Georges
    Chigarira, Beverly
    Sahu, Kamal Kant
    Balasubramanian, Ishwarya
    Caparas, Constance
    Thomas, Vinay Mathew
    Cohan, Jessica N.
    Pelletier, Kaitlyn
    Maughan, Benjamin L.
    Agarwal, Neeraj
    Swami, Umang
    Gupta, Sumati
    CANCERS, 2024, 16 (11)
12345